Advertisement

Contemporary Trends of Systemic Neoadjuvant and Adjuvant Intravesical Chemotherapy in Patients With Upper Tract Urothelial Carcinomas Undergoing Minimally Invasive or Open Radical Nephroureterectomy: Analysis of US Claims on Perioperative Outcomes and Health Care Costs

Published:December 23, 2021DOI:https://doi.org/10.1016/j.clgc.2021.11.016

      Abstract

      Introduction

      New evidence indicates that minimally invasive surgery (MIS) (laparoscopic or robotic-assisted [LNU, RANU]) reaches oncologic equivalence compared with Open Radical Nephroureterectomy (ORNU) for high-risk upper-tract urothelial carcinoma (UTUC). Recently, European Association of Urology (EAU) Guidelines suggested implementing neoadjuvant chemotherapy (NAC) to standard treatment to improve oncologic outcomes of high-risk UTUC. We aimed (1) To explore contemporary trends of MIS for RNU in the United States and to compare perioperative outcomes and costs with that of ORNU. (2) To determine the trends of NAC and postoperative intravesical chemotherapy (PIC) administration for high-risk UTUC and to assess their contribution to perioperative outcomes and costs.

      Patients and Methods

      The Optum Clinformatics Data Mart de-identified database was queried from 2003 to 2018 to retrospectively examine patients who had undergone LNU/RANU or ORNU with or without NAC and PIC. We evaluated temporal adoption trends, complications, and health care cost analyses. We obtained descriptive statistics and utilized multivariable regression modeling to assess outcomes.

      Results

      A total of n = 492 ORNU and n = 1618 LNU/RANU procedures were reviewed. The MIS approach was associated with a statistically significant lower risk of intraoperative complications (adjusted Odds Ratio [aOR], 0.48, 95% CI:0.24-0.96), risk of hospitalization costs (aOR: 0.62, 95% CI:0.49-0.78), and shorter hospital stay (aOR: 0.20, 95% CI:0.15-0.26) when compared to ORNU. Overall, adoption of NAC and PIC accounted for only n = 81 and n < 37 cases respectively. The implementation of NAC and higher number of cycles were associated with an increased probability of any complication rate (aOR: 2.06, 95% CI:1.26-3.36) and hospital costs (aOR: 2.12, 95% CI:1.33-3.38).

      Conclusion

      MIS has become the approach of choice for RNU in the US. Although recommended by guidelines, neither NAC nor postoperative bladder instillation of chemotherapy has been routinely incorporated into the clinical practice of patients with UTUC.

      Keywords

      Abbreviations:

      AUA (American Association of Urology), EAU (European Association of Urology), ORNU (Open radical nephroureterectomy), LNU (laparoscopic-assisted nephroureterectomy), UTUC (Upper-tract urothelial carcinoma), NAC (Neoadjuvant chemotherapy), MIBC (Muscle-invasive bladder carcinoma), CDM (Optum's Cliniformatics Data Mart), RNU (Radical nephroureterectomy), MIS (Minimally invasive surgery), OS (Overall survival), AC (Adjuvant chemotherapy), PIC (Postoperative intravesical chemotherapy)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Genitourinary Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Petros F.G.
        • Qiao W.
        • Singla N.
        • et al.
        Preoperative multiplex nomogram for prediction of high-risk nonorgan-confined upper-tract urothelial carcinoma.
        Urol Oncol. 2019; 37 (292.e1-292.e9Epub 2018 Dec 22. PMID: 30584035)https://doi.org/10.1016/j.urolonc.2018.12.002
        • Leow J.J.
        • Liu Z.
        • Tan T.W.
        • et al.
        Optimal management of upper tract urothelial carcinoma: current perspectives.
        Onco Targets Ther. 2020; 13 (PMID: 32021250; PMCID: PMC6954076): 1-15https://doi.org/10.2147/OTT.S225301
        • Rouprêt M.
        • Babjuk M.
        • Burger M.
        • et al.
        European Association of Urology Guidelines on upper urinary tract urothelial carcinoma: 2020 update.
        Eur Urol. 2021; 79 (Epub 2020 Jun 24. PMID: 32593530): 62-79https://doi.org/10.1016/j.eururo.2020.05.042
        • Golombos D.M.
        • Chughtai B.
        • Trinh Q.D.
        • et al.
        Minimally invasive vs open nephrectomy in the modern era: does approach matter?.
        World J Urol. 2017; 35 (Epub 2017 May 5. PMID: 28477204): 1557-1568https://doi.org/10.1007/s00345-017-2040-6
        • Hanna N.
        • Sun M.
        • Trinh Q.D.
        • et al.
        Propensity-score-matched comparison of perioperative outcomes between open and laparoscopic nephroureterectomy: a national series.
        Eur Urol. 2012; 61 (Epub 2011 Dec 22. PMID: 22209172): 715-721https://doi.org/10.1016/j.eururo.2011.12.026
        • Bozzini G.
        • Gastaldi C.
        • Besana U.
        • et al.
        Thulium-laser retrograde intra renal ablation of upper urinary tract transitional cell carcinoma: an ESUT Study.
        Minerva Urol Nephrol. 2021; 73 (Epub 2020 Jan 30. PMID: 32026668): 114-121https://doi.org/10.23736/S0393-2249.20.03689-9
        • Proietti S.
        • Marchioni M.
        • Eisner B.H.
        • et al.
        Conservative treatment of upper urinary tract carcinoma in patients with imperative indications.
        Minerva Urol Nephrol. 2021; 73 (Epub 2020 Feb 19. PMID: 32083422): 245-252https://doi.org/10.23736/S0393-2249.20.03710-8
        • Hwang E.C.
        • Sathianathen N.J.
        • Jung J.H.
        • Kim M.H.
        • Dahm P.
        • Risk M.C.
        Single-dose intravesical chemotherapy after nephroureterectomy for upper tract urothelial carcinoma.
        Cochrane Database Syst Rev. 2019; 5 (PMID: 31102534; PMCID: PMC6525634)CD013160https://doi.org/10.1002/14651858.CD013160.pub2
        • Fang D.
        • Li X.S.
        • Xiong G.Y.
        • Yao L.
        • He Z.S.
        • Zhou L.Q.
        Prophylactic intravesical chemotherapy to prevent bladder tumors after nephroureterectomy for primary upper urinary tract urothelial carcinomas: a systematic review and meta-analysis.
        Urol Int. 2013; 91 (Epub 2013 Aug 14. PMID: 23948770): 291-296https://doi.org/10.1159/000350508
        • Li K.
        • Xie W.
        • Gao L.
        • Huang G.
        • Zhou J.
        • Mei B.
        • Chen J.
        Impact of neoadjuvant chemotherapy on survival prognosis and pathological downstaging in patients presenting with high-risk upper tract urothelial carcinoma: a protocol for systematic review and meta-analysis.
        Medicine (Baltimore). 2020; 99 (PMID: 32358407; PMCID: PMC7440286): e20184https://doi.org/10.1097/MD.0000000000020184
        • Leow J.J.
        • Chang S.L.
        • Meyer C.P.
        • et al.
        Robot-assisted versus open radical prostatectomy: a contemporary analysis of an all-payer discharge database.
        Eur Urol. 2016; 70 (Epub 2016 Feb 11. PMID: 26874806): 837-845https://doi.org/10.1016/j.eururo.2016.01.044
        • Lindenauer P.K.
        • Pekow P.
        • Wang K.
        • Mamidi D.K.
        • Gutierrez B.
        • Benjamin E.M.
        Perioperative beta-blocker therapy and mortality after major noncardiac surgery.
        N Engl J Med. 2005; 353 (PMID: 16049209): 349-361https://doi.org/10.1056/NEJMoa041895
        • Wright J.D.
        • Ananth C.V.
        • Lewin S.N.
        • et al.
        Robotically assisted vs laparoscopic hysterectomy among women with benign gynecologic disease.
        JAMA. 2013; 309 (PMID: 23423414): 689-698https://doi.org/10.1001/jama.2013.186
        • Charlson M.E.
        • Pompei P.
        • Ales K.L.
        • MacKenzie C.R.
        A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.
        J Chronic Dis. 1987; 40 (PMID: 3558716): 373-383https://doi.org/10.1016/0021-9681(87)90171-8
        • Deyo R.A.
        • Cherkin D.C.
        • Ciol M.A.
        Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases.
        J Clin Epidemiol. 1992; 45 (PMID: 1607900): 613-619https://doi.org/10.1016/0895-4356(92)90133-8
        • Piszczek R.
        • Nowak Ł.
        • Krajewski W.
        • et al.
        Oncological outcomes of laparoscopic versus open nephroureterectomy for the treatment of upper tract urothelial carcinoma: an updated meta-analysis.
        World J Surg Oncol. 2021; 19 (PMID: 33882936; PMCID: PMC8061074): 129https://doi.org/10.1186/s12957-021-02236-z
        • Lee H.
        • Kim H.J.
        • Lee S.E.
        • Hong S.K.
        • Byun S.S.
        Comparison of oncological and perioperative outcomes of open, laparoscopic, and robotic nephroureterectomy approaches in patients with non-metastatic upper-tract urothelial carcinoma.
        PLoS One. 2019; 14 (PMID: 30620766; PMCID: PMC6324816)e0210401https://doi.org/10.1371/journal.pone.0210401
        • Simone G.
        • Papalia R.
        • Guaglianone S.
        • et al.
        Laparoscopic versus open nephroureterectomy: perioperative and oncologic outcomes from a randomised prospective study.
        Eur Urol. 2009; 56 (Epub 2009 Jun 21. PMID: 19560259): 520-526https://doi.org/10.1016/j.eururo.2009.06.013
        • Birtle A.
        • Johnson M.
        • Chester J.
        • et al.
        Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial.
        Lancet. 2020; 395 (Epub 2020 Mar 5. PMID: 32145825; PMCID: PMC7181180): 1268-1277https://doi.org/10.1016/S0140-6736(20)30415-3
        • Kim D.K.
        • Lee J.Y.
        • Kim J.W.
        • Hah Y.S.
        • Cho K.S.
        Effect of neoadjuvant chemotherapy on locally advanced upper tract urothelial carcinoma: a systematic review and meta-analysis.
        Crit Rev Oncol Hematol. 2019; 135 (Epub 2019 Jan 31. PMID: 30819447): 59-65https://doi.org/10.1016/j.critrevonc.2019.01.019
        • Hamaya T.
        • Hatakeyama S.
        • Tanaka T.
        • et al.
        Trends in the use of neoadjuvant chemotherapy and oncological outcomes for high-risk upper tract urothelial carcinoma: a multicentre retrospective study.
        BJU Int. 2021; (Epub ahead of print. PMID: 33484231)https://doi.org/10.1111/bju.15346
        • Stevenson S.M.
        • Danzig M.R.
        • Ghandour R.A.
        • et al.
        Cost-effectiveness of neoadjuvant chemotherapy before radical cystectomy for muscle-invasive bladder cancer.
        Urol Oncol. 2014; 32 (Epub 2014 Jul 4. PMID: 24998787): 1172-1177https://doi.org/10.1016/j.urolonc.2014.05.001
        • Zennami K.
        • Sumitomo M.
        • Takahara K.
        • et al.
        Two cycles of neoadjuvant chemotherapy improves survival in patients with high-risk upper tract urothelial carcinoma.
        BJU Int. 2021; 127 (Epub 2020 Sep 28. PMID: 32896105; PMCID: PMC7984033): 332-339https://doi.org/10.1111/bju.15230